ALung Systems announces closing of $14 Million Series A financing round ALung Systems.

The Company’s Hemolung device is likely to help many patients with acute respiratory failure to avoid intubation and invasive mechanical ventilation. This treatment is certainly expected to give a significant benefit over intubation and mechanical ventilation, in that it shall permit the patient to talk and eat, and avoid sedation, while providing the lungs the chance to heal. Related StoriesTeva presents brand-new Reslizumab data at European Respiratory Society International Congress 2015Study raises expect reducing life-threatening respiratory problems in infantsPhilips showcases most recent patient-driven rest and respiratory solutions at the European Respiratory Culture International Congress 2015’This financing allows ALung to complete its medical trial in Germany and subsequently commercialize the Hemolung Program,’ said Peter DeComo, CEO and Chairman of ALung.Meetings such as these are of great significance to advertise further scientific collaboration, not just on a global level, but a lot more so between your various experts employed in the complicated and fast evolving fields of prostate, bladder and renal cell tumor , says Prof. Per-Anders Abrahamsson from Malm – , person in the EMUC Organising Steering Committee on behalf of the EAU. Screening for prostate cancer, a much debated subject matter with far-reaching implications, is among the interesting issues on the meeting’s agenda. Relating to Prof. Jos – Baselga, Barcelona , member of the EMUC Organising Steering Committee with respect to the ESMO: New substances for the treatments of castrate-resistant prostate cancer and advanced renal cell carcinoma will become discussed.